

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10596397	
	Filing Date		2007-04-19	
	First Named Inventor	BISSONNETTE, Luc		
	Art Unit	1634		
	Examiner Name	GREENE, JAIME		
	Attorney Docket Number	056694-0010		

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	6197941		2001-03-06	ZAMPONI, et al			
	2	6589731		2003-07-08	CHEN, et al			
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	20020177136		2002-11-28	MCBRANCH, et al			
	2	20030152995		2003-08-14	HANNAH			
	3	20020068295		2002-06-06	MADOU, et al			
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10596397
Filing Date	2007-04-19
First Named Inventor	BISSONNETTE, Luc
Art Unit	1634
Examiner Name	GREENE, JAIME
Attorney Docket Number	056694-0010

1	WO02081735			2002-10-17	LECLERC, et al		<input type="checkbox"/>
2	WO02095052			2002-11-28	HYLDIG-NIELSEN, et al		<input type="checkbox"/>
3	WO9802499			1998-01-29	LECLERC, et al		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	ALIVISATOS, P., Pure Appl. Chem., Vol 72, Nos. 1-2, pp. 3-9, 2000	<input type="checkbox"/>
	2	BEAUCAGE, S., Curr Med Chem, Vol. 8, No. 10, pp. 1213-1244, 2001	<input type="checkbox"/>
	3	BEIER, M. and HOHEISEL, J., Nucleic Acids Research, 1999, Vol 27, No. 9 pp. 1970-1977	<input type="checkbox"/>
	4	BRANDT, O. et al., Nucleic Acids Research, 2003, Vol. 31, No. 19	<input type="checkbox"/>
	5	BRANDT, O. and HOHEISEL, J., TRENDS in Biotechnology, Vol. 22, No. 12, December 2004	<input type="checkbox"/>
	6	BRAUN, E. et al., Nature, Vol. 391, 19 February 1998 pp. 775-778	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10596397
Filing Date	2007-04-19
First Named Inventor	BISSONNETTE, Luc
Art Unit	1634
Examiner Name	GREENE, JAIME
Attorney Docket Number	056694-0010

7	BRUST, M. and KIELY, C., Colloids and Surfaces A: Physicochem. Eng. Aspects 202, 2002, 175-186	<input type="checkbox"/>
8	CHAN, W. and NIE, S., Science, Vol. 281, 25 Sept. 1998, pp. 2016-2018	<input type="checkbox"/>
9	COFFER, J., et al., Appl. Phys. Lett. 69 (25):3851 December 1996	<input type="checkbox"/>
10	Elbashir, S. et al., The EMBO Journal, Vol. 20 No. 23 PP 6877-6888, 2001	<input type="checkbox"/>
11	FREDRICKS, D. and RELMAN, D. Clinical Infectious Diseases, Vol 29, pp. 475-88, 1999	<input type="checkbox"/>
12	FREIER, S.M. et al., Proc. Natl. Acad. Sci. USA, Vol. 83 pp. 9373-9377, December 1986	<input type="checkbox"/>
13	GAYLORD, B. et al., Proc. Natl. Acad. Sci. Vol. 99, No. 17, pp. 10954-10957, August 20, 2002	<input type="checkbox"/>
14	GERMINI, A. et al., J Agric. Food Chem. Vol. 52, pp. 4535-4540, 2004.	<input type="checkbox"/>
15	HO, H. et al., Agnew. Chem. Int. Ed. Vol. 41, No. 9, pp. 1548-155, 2002	<input type="checkbox"/>
16	HO, H. et al., Polymer Preprints 2002, Vol. 43, No. 1, pp. 133-34	<input type="checkbox"/>
17	HUANG, J. et al., Polymer Bulletin, Vol. 36, pp. 337-340, 1996	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10596397
Filing Date	2007-04-19
First Named Inventor	BISSONNETTE, Luc
Art Unit	1634
Examiner Name	GREENE, JAIME
Attorney Docket Number	056694-0010

18	JAIN, K. Pharmacogenomics 2000, Vol. 1, No. 3, pp. 289-307	<input type="checkbox"/>
19	KRICKA, L. J., Ann Clin Biochem 2002, Vol. 39 pp. 114-129	<input type="checkbox"/>
20	KRISHNAMOORTHY, K. et al., Chem Commun, 2004, pp. 820-821	<input type="checkbox"/>
21	KWOH, D.Y. et al., Proc Natl Acad Sci USA, Vol. 86, pp. 1173-1177, February 1989	<input type="checkbox"/>
22	KWOH, B. and KWOH, J. Am Biotechnol Lab 1990, pp. 14-25	<input type="checkbox"/>
23	LIU, A. and ANZAI, J. ANal Chem 2004, Vol. 76, pp. 2975-2980	<input type="checkbox"/>
24	LIZARDI, P. et al., Biotechnology, Vol. 6, October 1988 pp. 1197-1202	<input type="checkbox"/>
25	MALEK, L. et al., Methods in Molecular Biology, Vol. 28, pp. 253-260	<input type="checkbox"/>
26	PENNER, R. Acc Chem Res 2000, Vol. 33, pp. 78-86	<input type="checkbox"/>
27	PORATH, J. Method Enzymol. pp. 13-30, 1974	<input type="checkbox"/>
28	RAY, A. and NORDEN, B. The FASEB Journal, Vol. 14, pp.1041-1060, June 2000	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10596397
Filing Date	2007-04-19
First Named Inventor	BISSONNETTE, Luc
Art Unit	1634
Examiner Name	GREENE, JAIME
Attorney Docket Number	056694-0010

29	REYNOLDS, M. et al., Nucleic Acids Research, Vol. 24, No. 22, pp. 4584-4591, 1996	<input type="checkbox"/>
30	ROSSETTO, F. and NIEBOER, E., Journal of Inorganic Biochemistry, Vol. 54, pp. 167-186, 1994	<input type="checkbox"/>
31	STORHOFF, J. and MIRKIN, C., Chem Rev 1999, Vol. 99, pp. 1849-1862	<input type="checkbox"/>
32	TURNER, D. et al., J. Am Chem Soc 1987, Vol. 109, pp. 3783-3785	<input type="checkbox"/>
33	VO-DINH, T. and CULLUM, B. Fresenius J Anal Chem, 2000, Vol. 366, pp. 540-551	<input type="checkbox"/>
34	WARNER, M.G. and HUTCHISON, J. E., Nature Materials, Vol. 2, pp. 272- 277, April 2003	<input type="checkbox"/>
35	DORE, et al., J. Am. Chem Soc 7, Vol 126:13 pp. 4240-4244, April 2004	<input type="checkbox"/>
36	FRITZ, J. et al., Proc. Natl Acad Sci, Vol 99, No. 22, pp. 14142-14146, October 2002	<input type="checkbox"/>
37	HO, H. et al., J Am Chem Soc., Vol 126: 1384-1387, 2004	<input type="checkbox"/>
38	LUKKARI, J. et al., J Am Chem Soc., Vol 123:6083-6091, 2001	<input type="checkbox"/>
39	NIELSEN, P. et al., Current Issues Molec Biol., Vol 1, No 2, pp. 89-104, 1999	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10596397
Filing Date		2007-04-19
First Named Inventor	BISSONNETTE, Luc	
Art Unit	1634	
Examiner Name	GREENE, JAIME	
Attorney Docket Number	056694-0010	

40	NILSSON, K., et al., Nature Materials, Vol 2:419-424, June 2003	<input type="checkbox"/>
41	NILSSON, K., et al., Proc natl Acad Sci USA, Vol. 100, No. 18, pp. 10170-10174, September 2, 2003	<input type="checkbox"/>
42	SASTRY, M., Pure Appl Chem., Vol. 74, No. 9, pp. 1621-1630, 2002	<input type="checkbox"/>
43	ZIAO, S., et al., J Nanoparticle Res., Vol. 126:1384-1387, 2004	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10596397
Filing Date	2007-04-19
First Named Inventor	BISSONNETTE, Luc
Art Unit	1634
Examiner Name	GREENE, JAIME
Attorney Docket Number	056694-0010

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Nicholas A. Kees/	Date (YYYY-MM-DD)	2007-08-13
Name/Print	Nicholas A. Kees	Registration Number	29552

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.